Nevirapine Lp Accord

Nevirapine, the active ingredient in Nevirapine Lp Accord, is a non‑nucleoside reverse transcriptase inhibitor presented as an oral formulation for oral use. It is employed in the treatment of HIV‑1 infection in adults and children as part of combination antiretroviral therapy.

GNH USA supplies Nevirapine Lp Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides full regulatory documentation for export to multiple regions, ensuring timely delivery and compliance with local import requirements.

Nevirapine is used in antiretroviral regimens targeting HIV‑1 replication. - HIV‑1 infection in adults: reduces viral load as part of combination therapy. - HIV‑1 infection in children: contributes to viral suppression when combined with other antiretrovirals. - Prevention of mother‑to‑child transmission of HIV: used with other agents to lower the risk of vertical transmission.

Nevirapine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Rash: mild to moderate skin eruptions. - Nausea: transient gastrointestinal discomfort. - Headache: mild cranial pain. - Fatigue: general tiredness. - Abdominal pain: mild stomach discomfort. - Dizziness: occasional light‑headedness.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction requiring immediate medical attention. - Hepatotoxicity: elevated liver enzymes or liver failure. - Severe hypersensitivity: fever, malaise, and systemic rash. - Hepatic necrosis: rare but life‑threatening liver injury. - Anemia: significant drop in red blood cell count.

When prescribing Nevirapine, clinicians should observe several safety considerations. - Liver function monitoring: assess baseline and periodic hepatic enzymes. - Hepatitis B/C co‑infection: evaluate risk of severe liver injury. - Pregnancy and breastfeeding: weigh benefits against potential fetal or infant risks. - Drug resistance: avoid monotherapy and ensure adherence to combination regimens. - Concomitant CYP3A4 inducers: adjust therapy as they may lower nevirapine levels. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Nevirapine interacts with several medicines that can alter its plasma concentrations or increase toxicity.

Major Interactions (Avoid): - Rifampicin: strong CYP3A4 inducer that markedly reduces nevirapine exposure. - Carbamazepine: enzyme inducer leading to sub‑therapeutic levels. - St. John’s wort: herbal inducer that may decrease efficacy.

Moderate Interactions (Monitor Closely): - Protease inhibitors (e.g., ritonavir): can increase nevirapine concentrations and risk hepatotoxicity. - Azole antifungals (e.g., ketoconazole): may raise nevirapine levels. - Oral contraceptives: nevirapine may reduce hormonal efficacy. - Warfarin: potential alteration of anticoagulant effect.